SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy Post published:December 20, 2024 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #183: UW Madison’s Psychedelic Symposium; MindMed Doses First Phase 3 Patient; Beckley’s IV Psilocin Readout; Psilocybin for COVID Clinicians Post published:December 18, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding Post published:December 10, 2024 Post category:Psychedelic Bulletin/Pα+
Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the Field Post published:December 5, 2024 Post category:Interviews/Pα+
Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain Future Post published:November 30, 2024 Post category:Analysis/News/Pα+
Q3’24 Survey: What are Psychedelics Investors Concerned About? Post published:November 27, 2024 Post category:Analysis/News/Pα+
Q3’24 Survey: What are Psychedelics Investors Excited About? Post published:November 25, 2024 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #181: Last-Minute Changes to Colorado’s Psychedelics Rules; Cybin’s Impressive 12-Month Data Overshadowed by Small N and Controversial Marketing Move Post published:November 22, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #180: Mass. Psychedelics Ballot Post-Mortem Begins; Cybin Commences Phase 3; CaaMTech Claims It’s Solved Functional Unblinding Post published:November 15, 2024 Post category:Psychedelic Bulletin/Pα+
Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future of Psychedelic Research and Regulation Under Trump or Harris Post published:November 4, 2024 Post category:Analysis/News/Pα+